| Literature DB >> 25200284 |
Abstract
Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25200284 DOI: 10.1038/nrcardio.2014.132
Source DB: PubMed Journal: Nat Rev Cardiol ISSN: 1759-5002 Impact factor: 32.419